Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.
Read original at benzingaStocks · News reference
8-K filing — Edgewise Therapeutics, Inc. (EWTX)
Filed: 2026-08-06 AccNo: 0001104659-26-091671 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 12:05 PM
- Checked
- Aug 6, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over losses of $(0.34) per
Read original at benzingaEvercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
Read original at benzinga